Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Lexicon Pharmaceuticals, Inc is a biotechnology business based in the US. Lexicon Pharmaceuticals shares (LXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Lexicon Pharmaceuticals employs 78 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.39|
|52-week range||$1.03 - $9.43|
|50-day moving average||$4.44|
|200-day moving average||$5.65|
|Wall St. target price||$9.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.37|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||-12.20%|
|3 months (2021-04-29)||-12.90%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Valuing Lexicon Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lexicon Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lexicon Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $82.5 million.
The EBITDA is a measure of a Lexicon Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$16 million|
|Gross profit TTM||$-129,055,000|
|Return on assets TTM||-29.2%|
|Return on equity TTM||-12.46%|
|Market capitalisation||$512.6 million|
TTM: trailing 12 months
There are currently 4.4 million Lexicon Pharmaceuticals shares held short by investors – that's known as Lexicon Pharmaceuticals's "short interest". This figure is 24.4% up from 3.5 million last month.
There are a few different ways that this level of interest in shorting Lexicon Pharmaceuticals shares can be evaluated.
Lexicon Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Lexicon Pharmaceuticals shares currently shorted divided by the average quantity of Lexicon Pharmaceuticals shares traded daily (recently around 1.2 million). Lexicon Pharmaceuticals's SIR currently stands at 3.79. In other words for every 100,000 Lexicon Pharmaceuticals shares traded daily on the market, roughly 3790 shares are currently held short.
However Lexicon Pharmaceuticals's short interest can also be evaluated against the total number of Lexicon Pharmaceuticals shares, or, against the total number of tradable Lexicon Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lexicon Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Lexicon Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0745% of the tradable shares (for every 100,000 tradable Lexicon Pharmaceuticals shares, roughly 75 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lexicon Pharmaceuticals.
Find out more about how you can short Lexicon Pharmaceuticals stock.
We're not expecting Lexicon Pharmaceuticals to pay a dividend over the next 12 months.
Lexicon Pharmaceuticals's shares were split on a 1:7 basis on 20 May 2015. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexicon Pharmaceuticals shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Lexicon Pharmaceuticals shares which in turn could have impacted Lexicon Pharmaceuticals's share price.
Over the last 12 months, Lexicon Pharmaceuticals's shares have ranged in value from as little as $1.03 up to $9.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexicon Pharmaceuticals's is 1.4788. This would suggest that Lexicon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. .
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.